Vanguard Capital Management Establishes 5.05% Stake in Ionis Pharmaceuticals Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.05% passive ownership stake in Ionis Pharmaceuticals Inc (IONS). As of the event date on March 31, 2026, Vanguard beneficially owns 8,344,732 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 8,344,732 shares, while maintaining sole voting power over 1,226,402 shares. This position includes holdings managed by various affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. The filing was made under Rule 13d-1(b), certifying that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This represents a significant increase from a previous 0% ownership level, establishing Vanguard as a major institutional shareholder in the biotechnology company.